Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications

Tytuł:
Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications
Autorzy:
Peter Rambau
Linda E. Kelemen
Helen Steed
May Lynn Quan
Prafull Ghatage
Martin Köbel
Temat:
ovarian cancer
endometrioid
estrogen receptor
progesterone receptor
hormonal therapy
prognosis
Biology (General)
QH301-705.5
Chemistry
QD1-999
Źródło:
International Journal of Molecular Sciences, Vol 18, Iss 3, p 515 (2017)
Wydawca:
MDPI AG, 2017.
Rok publikacji:
2017
Kolekcja:
LCC:Biology (General)
LCC:Chemistry
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
1422-0067
Relacje:
http://www.mdpi.com/1422-0067/18/3/515; https://doaj.org/toc/1422-0067
DOI:
10.3390/ijms18030515
Dostęp URL:
https://doaj.org/article/bbcc883496f94c438cb08b0188fb7b07  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.bbcc883496f94c438cb08b0188fb7b07
Czasopismo naukowe
This paper aims to validate whether hormone receptor expression is associated with longer survival among women diagnosed with ovarian endometrioid carcinoma (EC), and whether it identifies patients with stage IC/II tumors with excellent outcome that could be spared from toxic chemotherapy. Expression of estrogen receptor (ER) and progesterone receptor (PR) was assessed on 182 EC samples represented on tissue microarrays using the Alberta Ovarian Tumor Type (AOVT) cohort. Statistical analyses were performed to test for associations with ovarian cancer specific survival. ER or PR expression was present in 87.3% and 86.7% of cases, respectively, with co-expression present in 83.0%. Expression of each of the hormonal receptors was significantly higher in low-grade tumors and tumors with squamous differentiation. Expression of ER (Hazard Ratio (HR) = 0.18, 95% confidence interval 0.08–0.42, p = 0.0002) and of PR (HR = 0.22, 95% confidence interval 0.10–0.53, p = 0.0011) were significantly associated with longer ovarian cancer specific survival adjusted for age, grade, treatment center, stage, and residual disease. However, the five-year ovarian cancer specific survival among women with ER positive stage IC/II EC was 89.0% (standard error 3.3%) and for PR positive tumors 89.9% (standard error 3.2%), robustly below the 95% threshold where adjuvant therapy could be avoided. We validated the association of hormone receptor expression with ovarian cancer specific survival independent of standard predictors in an independent sample set of EC. The high ER/PR co-expression frequency and the survival difference support further testing of the efficacy of hormonal therapy in hormone receptor-positive ovarian EC. The clinical utility to identify a group of women diagnosed with EC at stage IC/II that could be spared from adjuvant therapy is limited.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies